Vivos Therapeutics (VVOS) Enterprise Value (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Enterprise Value for 7 consecutive years, with $4.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value fell 75.63% year-over-year to $4.6 million in Q2 2026; TTM through Jun 2026 was $4.6 million, a 75.63% decrease from a year earlier, with the FY2025 full-year figure at $16.8 million, down 11.8% from the prior year.
• Enterprise Value was $4.6 million for Q2 2026 at Vivos Therapeutics, down from $13.7 million in the prior quarter.
• Over five years, Enterprise Value peaked at $43.8 million in Q1 2022 and troughed at $648303.5 in Q2 2024.
• A 5-year average of $14.1 million and a median of $12.4 million in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value tumbled 96.82% in 2023 and surged 2791.3% in 2025, its largest moves.
• Over 5 years, Enterprise Value stood at $5.7 million in 2022, then jumped by 135.98% to $13.5 million in 2023, then jumped by 40.51% to $19.0 million in 2024, then declined by 11.8% to $16.8 million in 2025, then slumped by 72.75% to $4.6 million in 2026.
• The last three Enterprise Value figures came in at $4.6 million (Q2 2026), $13.7 million (Q1 2026), and $16.8 million (Q4 2025), per Business Quant data.